A Randomised, Double-Blind, Parallel-Group, Multicentre, Phase III Study to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Rate of Vaso-Occlusive Crises in Paediatric Patients with Sickle Cell Disease (HESTIA3)
Phase of Trial: Phase III
Latest Information Update: 12 Feb 2019
At a glance
- Drugs Ticagrelor (Primary)
- Indications Sickle cell anaemia
- Focus Therapeutic Use
- Acronyms HESTIA3
- Sponsors AstraZeneca
- 15 Oct 2018 Planned End Date changed from 30 Oct 2020 to 9 Nov 2020.
- 15 Oct 2018 Planned primary completion date changed from 30 Oct 2020 to 9 Nov 2020.
- 02 Oct 2018 Status changed from not yet recruiting to recruiting.